Novel application of synchrotron x-ray computed tomography for ex-vivo imaging of subcutaneously injected polymeric microsphere suspension formulations.
Animals
Biocompatible Materials
/ chemistry
Contrast Media
/ chemistry
Drug Compounding
Imaging, Three-Dimensional
Injections, Subcutaneous
Microspheres
Polylactic Acid-Polyglycolic Acid Copolymer
/ chemistry
Radiographic Image Enhancement
Suspensions
/ chemistry
Swine
Synchrotrons
Tissue Scaffolds
/ chemistry
Tomography, X-Ray Computed
/ methods
X-ray computed tomography
depot
imaging
microsphere
subcutaneous injection
vehicle
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
14 May 2020
14 May 2020
Historique:
received:
09
12
2019
accepted:
14
04
2020
entrez:
16
5
2020
pubmed:
16
5
2020
medline:
2
10
2020
Statut:
epublish
Résumé
Subcutaneously or intramuscularly administered biodegradable microsphere formulations have been successfully exploited in the management of chronic conditions for over two decades, yet mechanistic understanding of the impact of formulation attributes on in vivo absorption rate from such systems is still in its infancy. Suspension formulation physicochemical attributes may impact particulate deposition in subcutaneous (s.c.) tissue. Hence, the utility of synchrotron X-ray micro-computed tomography (μCT) for assessment of spatial distribution of suspension formulation components (PLG microspheres and vehicle) was evaluated in a porcine s.c. tissue model. Optical imaging of dyed vehicle and subsequent microscopic assessment of microsphere deposition was performed in parallel to compare the two approaches. Our findings demonstrate that synchrotron μCT can be applied to the assessment of microsphere and vehicle distribution in s.c. tissue, and that microspheres can also be visualised in the absence of contrast agent using this approach. The technique was deemed superior to optical imaging of macrotomy for the characterisation of microsphere deposition owing to its non-invasive nature and relatively rapid data acquisition time. The method outlined in this study provides a proof of concept feasibility for μCT application to determining the vehicle and suspended PLG microspheres fate following s.c. injection. A potential application for our findings is understanding the impact of injection, device and formulation variables on initial and temporal depot geometry in pre-clinical or ex-vivo models that can inform product design. Graphical abstract.
Identifiants
pubmed: 32409985
doi: 10.1007/s11095-020-02825-9
pii: 10.1007/s11095-020-02825-9
pmc: PMC7225200
doi:
Substances chimiques
Biocompatible Materials
0
Contrast Media
0
Suspensions
0
Polylactic Acid-Polyglycolic Acid Copolymer
1SIA8062RS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
97Références
Opt Express. 2015 Dec 14;23(25):32859-68
pubmed: 26699073
Eur J Pharm Sci. 2014 Oct 1;62:65-75
pubmed: 24878388
Drug Metab Dispos. 2014 Nov;42(11):1881-9
pubmed: 25100673
Diabetes Obes Metab. 2018 Jan;20(1):165-172
pubmed: 28685973
Diabetes Technol Ther. 2011 Nov;13(11):1145-54
pubmed: 21751887
Philos Trans A Math Phys Eng Sci. 2015 Jun 13;373(2043):
pubmed: 25939626
J Microsc. 2002 Apr;206(Pt 1):33-40
pubmed: 12000561
J Pharm Sci. 2015 Feb;104(2):301-6
pubmed: 25411114
AAPS J. 2012 Sep;14(3):559-70
pubmed: 22619041
J Synchrotron Radiat. 2015 May;22(3):828-38
pubmed: 25931103
J Biophotonics. 2017 Jun;10(6-7):870-877
pubmed: 26776883
Vet Pathol. 2012 Mar;49(2):344-56
pubmed: 21441112
J Diabetes Sci Technol. 2013 Jan 01;7(1):227-37
pubmed: 23439181
BMC Res Notes. 2011 Sep 09;4:344
pubmed: 21906300
Sci Rep. 2016 Jul 13;6:29653
pubmed: 27405824
J Control Release. 2014 Sep 28;190:240-53
pubmed: 24929039
J Control Release. 2017 Nov 28;266:187-197
pubmed: 28947395
Int J Neuropsychopharmacol. 2005 Mar;8(1):27-36
pubmed: 15710053
Exp Biol Med (Maywood). 2002 Oct;227(9):794-8
pubmed: 12324659
Curr Drug Targets. 2015;16(6):672-82
pubmed: 25418857
J Pharm Sci. 2016 Aug;105(8):2255-9
pubmed: 27378678
Eur J Pharm Sci. 2015 Nov 15;79:96-101
pubmed: 26341408
Int J Pharm. 2017 Jul 15;527(1-2):31-41
pubmed: 28487188